Andere talen Omega Therapeutics, Inc.

Aandelen

OMGA

US68217N1054

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,27 ^USD	-3,40%		-5,42%	-24,58%

16/04	Omega Therapeutics, Inc. Wijst Barbara Chan aan als hoofdaccountant, met ingang van 31 mei 2024	CI
09/04	Omega Therapeutics, Inc. Presenteert nieuwe preklinische gegevens op de AACR 2024 ter ondersteuning van het potentieel van epigenomische precisiecontrole	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting	23/04
Omega Therapeutics CFO Joshua Reed to Depart	16/04
Omega Therapeutics, Inc. Announces Executive Changes, Effective as of May 31, 2024	16/04
Omega Therapeutics, Inc. Designates Barbara Chan as Principal Accounting Officer, Effective as of May 31, 2024	16/04
Flagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio Sciences	09/04
Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control	09/04
Omega Therapeutics, Inc. Presents New Preclinical Data At AACR 2024 Supporting the Potential of Precision Epigenomic Control	09/04
Omega Therapeutics Cuts Headcount by 35%, Narrows Q4 Loss	28/03
Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update	28/03
Omega Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Omega Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03
North American Morning Briefing : Stocks Set for -2-	28/03
North American Morning Briefing : Investors -2-	21/03
Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024	06/03
Omega Therapeutics Announces Research Collaboration with Novo Nordisk to Develop Novel Therapeutic for Obesity Management	05/01
Sector Update: Health Care Stocks Stronger Late Afternoon	04/01
Top Midday Gainers	04/01
Novo Nordisk Collaborates With Omega Therapeutics, Cellarity on Cardiometabolic Diseases Research	04/01
Top Premarket Gainers	04/01
Wegovy maker Novo Nordisk enters research tie-ups with US biotech firms	04/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Omega Therapeutics, Inc.

Aandelen

OMGA

US68217N1054

Andere talen

Filters